# Impact of Switching to NNRTI-based Therapy on the Quality of Life of HIV-infected Patients With Virological Suppression

> **NCT02191202** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 283 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)

## Key facts

- **NCT ID:** NCT02191202
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2006-02
- **Final completion:** —
- **Target enrollment:** 283 (ACTUAL)
- **Last updated:** 2014-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02191202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02191202, "Impact of Switching to NNRTI-based Therapy on the Quality of Life of HIV-infected Patients With Virological Suppression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02191202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*